Application of the dynamic contrast enhanced MRI combined with magnetic resonance spectroscopy in diagnosis of prostate cancer_West China Medical Journal

Authors：

HE Yakun ,  XU Guohui , REN Jing , WANG Min , DONG Xiaolei , LU Hao , HE Changjiu

Department of Medical Imaging, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

XU Guohui, Email: 273795600@qq.com

Keywords：

Prostate cancer; Magnetic resonance imaging; Dynamic contrast enhanced; Spectroscopy

DOI：

10.7507/1002-0179.201508152

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the application of the dynamic contrast enhanced MRI (DCE-MRI ) combined with magnetic resonance spectroscopy (MRS) in the diagnosis of prostate cancer. Method A total of 60 patients with prostate cancer and 60 patients with benign prostatic hyperplasia diagnoses in Sichuan Cancer Hospital from January 2011 to January 2014 were included as prostate cancer group and proliferative group respectively. Sixty healthy individuals during the same period were included as the control group. We used Siemens Avanto 1.5 T high field superconducting MRI for DCE-MRI scan and MRS scan. After the MRS scan was finished, we used the workstation spectroscopy tab spectral analysis. Eventually we got the crest lines of prostate metabolites choline (Cho), creatine (Cr) and citrate (Cit). Then we calculated Cho/Cit, (Cho+Cr)/Cit and their average. Results Comparing the signal value in 21 seconds, 1 minute, 2 minutes of DCE-MRI, the differences among the three groups were statistically significant (P<0.05). Comparing the results of spectral analysis, the differences among the three groups were statistically significant (P<0.05). The sensitivity was 89.67%, the specificity was 95.45% and the accuracy was 94.34% when using DCE-MRI combined with MRS. Conclusion DCE-MRI combined with MRS greatly improves the sensitivity, specificity and accuracy of the diagnosis of prostate cancer; it has a great application value in the diagnosis of prostate cancer.

Citation： HE Yakun, XU Guohui, REN Jing, WANG Min, DONG Xiaolei, LU Hao, HE Changjiu. Application of the dynamic contrast enhanced MRI combined with magnetic resonance spectroscopy in diagnosis of prostate cancer. West China Medical Journal, 2017, 32(7): 1042-1045. doi: 10.7507/1002-0179.201508152 Copy

1.	李呜, 张思维, 马建辉, 等. 中国部分市县前列腺癌发病趋势比较研究. 中华泌尿外科杂志, 2009, 30(6): 368-370.
2.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
3.	Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol, 2008, 9(5): 445-452.
4.	Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 2010, 46(4): 765-781.
5.	Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med, 2009, 61(4): 842-850.
6.	Langer DL, Van Der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on Mr imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. Radiology, 2008, 249(3): 900-908.
7.	Langer DL, Van Der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2009, 30(2): 327-334.
8.	Zhang L, Wu S, Guo LR, et al. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J Androl, 2009, 11(1): 9-13.
9.	Vos PC, Hambrock T, Hulsbergen-Van De Kaa CA, et al. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys, 2008, 35(3): 888-899.
10.	Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol, 2009, 19(3): 770-778.
11.	Mcmahon CJ, Bloch BN, Lenkinski RE, et al. Dynamic contrast-enhanced Mr imaging in the evaluation of patients with prostate cancer. Magn Reson Imaging Clin N Am, 2009, 17(2): 363-383.
12.	Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonanceimaging in the evaluation of the prostate. Top Magn Reson Imaging, 2008, 19(6): 273-284.
13.	Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm². AJR Am J Roentgenol, 2010, 194(1): W33-W37.
14.	Casciani E, Polettini E, Carmenini E, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol, 2008, 190(5): 1187-1192.
15.	王霄英, 周良平, 李飞宇, 等. 前列腺癌的 MR 波谱特征与 Gleason 评分的关系. 中华放射学杂志, 2006, 40(11): 1181-1184.
16.	张鹏. 磁共振成像动态增强扫描在前列腺癌诊断中的价值. 实用医技杂志, 2009, 16(3): 168-170.
17.	史浩, 武乐斌, 丁红宇, 等. MR 动态增强、扩散成像和波谱分析在前列腺癌诊断中的价值. 中华放射学杂志, 2006, 40(7): 678-683.
18.	Westphalen AC, Kurhanewicz J, Cunha RM, et al. T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol, 2009, 35(2): 171-180; discussion 181-182.
19.	Fuchsjäger M, Akin O, Shukla-Dave A, et al. The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin Adv Hematol Oncol, 2009, 7(3): 193-202.

1. 李呜, 张思维, 马建辉, 等. 中国部分市县前列腺癌发病趋势比较研究. 中华泌尿外科杂志, 2009, 30(6): 368-370.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
3. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol, 2008, 9(5): 445-452.
4. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 2010, 46(4): 765-781.
5. Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med, 2009, 61(4): 842-850.
6. Langer DL, Van Der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on Mr imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. Radiology, 2008, 249(3): 900-908.
7. Langer DL, Van Der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2009, 30(2): 327-334.
8. Zhang L, Wu S, Guo LR, et al. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J Androl, 2009, 11(1): 9-13.
9. Vos PC, Hambrock T, Hulsbergen-Van De Kaa CA, et al. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys, 2008, 35(3): 888-899.
10. Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol, 2009, 19(3): 770-778.
11. Mcmahon CJ, Bloch BN, Lenkinski RE, et al. Dynamic contrast-enhanced Mr imaging in the evaluation of patients with prostate cancer. Magn Reson Imaging Clin N Am, 2009, 17(2): 363-383.
12. Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonanceimaging in the evaluation of the prostate. Top Magn Reson Imaging, 2008, 19(6): 273-284.
13. Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm². AJR Am J Roentgenol, 2010, 194(1): W33-W37.
14. Casciani E, Polettini E, Carmenini E, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol, 2008, 190(5): 1187-1192.
15. 王霄英, 周良平, 李飞宇, 等. 前列腺癌的 MR 波谱特征与 Gleason 评分的关系. 中华放射学杂志, 2006, 40(11): 1181-1184.
16. 张鹏. 磁共振成像动态增强扫描在前列腺癌诊断中的价值. 实用医技杂志, 2009, 16(3): 168-170.
17. 史浩, 武乐斌, 丁红宇, 等. MR 动态增强、扩散成像和波谱分析在前列腺癌诊断中的价值. 中华放射学杂志, 2006, 40(7): 678-683.
18. Westphalen AC, Kurhanewicz J, Cunha RM, et al. T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol, 2009, 35(2): 171-180; discussion 181-182.
19. Fuchsjäger M, Akin O, Shukla-Dave A, et al. The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin Adv Hematol Oncol, 2009, 7(3): 193-202.

West China Medical Journal

Application of the dynamic contrast enhanced MRI combined with magnetic resonance spectroscopy in diagnosis of prostate cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content